AKAlima A. Khamidulla

Alima A. Khamidulla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alima A. Khamidulla has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bibliometric Analysis of Alpha‐Synuclein Determination by Biopsy in Peripheral Tissues of Patients With Parkinson’s Disease

    by Aigerim B. Utegenova, Aigul P. Yermagambetova, Gulnar B. Kabdrakhmanova, Alima A. Khamidulla, Zhanylsyn U. Urasheva, Nazym K. Kenzhinа, Zhanna Zhussupova, Gulzhanat N. Nurlanova

    Study Evaluation: The bibliometric analysis of the published results of the alpha‐synuclein ( α ‐syn) detection study in the peripheral tissues of patients with Parkinson’s disease was carried out by us to study scientific activity and scientific productivity, to measure the quantitative and qualitative characteristics of scientific publications, author productivity, and citation of works, as well as the degree of interrelation between authors, journals, institutes, and countries. Purpose: This study is aimed at bibliometrically analyzing the results of studies on the detection of α ‐syn in peripheral tissue biopsy of patients with Parkinson’s disease from 2013 to 2023. Methods: The data was extracted from the Scopus database collection using an inclusive search strategy. Performance analysis and science mapping were conducted using RStudio v.4.3.1 with the bibliometrix R‐package. The analyzed data encompassed trends in publication and citation and the identification of leading institutions, primary sources, authors, and collaborative countries. Results: A total of 124 relevant studies from 53 different sources were thoroughly analyzed. The analysis included the materials of 843 authors, which together gave an impressive average of 37.67 citations per document over the past decade. The annual growth rate in this area of research, according to calculations, was 10.84%, indicating a steady increase in the number of publications over the study period. The huge volume of research results is highlighted by the inclusion of 231 unique keywords of authors. Conclusion: Studies on the detection of pathological α ‐syn in peripheral tissues for early morphological verification of the diagnosis of Parkinson’s disease are relevant in clinical neurology. α ‐syn detected in the skin biopsy of patients on the basis of this study and data from the world literature meets the requirements for biomarkers.


  • Open Access

    Some Serologic Biomarkers of Multiple Sclerosis Activity: A Narrative Review

    by Alima A. Khamidulla, Zhanylsyn U. Urasheva, Gulnar B. Kabdrakhmanova, Aigul P. Yermagambetova, Aigerim B. Utegenova


  • Open Access

    Bibliometric Analysis of the Role of Occludin in the Pathogenesis of Stroke

    by Zhanylsyn U. Urasheva, Gulnar B. Kabdrakhmanova, Aigul P. Yermagambetova, Aigerim B. Utegenova, Nazgul A. Seitmaganbetova, Ondassyn M. Aliyev, Saulesh S. Kurmangaliyeva, Nazym K. Kenzhina, Yergen Z. Kurmambayev, Alima A. Khamidulla

    Over the past decade, there has been a notable surge in research dedicated to unraveling the intricate role of tight junction proteins in blood–brain barrier (BBB) damage associated with ischemic stroke. This bibliometric analysis explores the expansive landscape of occludin research, a key tight junction protein, during the years 2000–2023, shedding light on the global scientific contributions, collaborations, and emerging trends in this critical area of stroke pathogenesis. China and the United States emerge as significant contributors, underscoring their prominence in advancing our understanding of tight junction proteins. Occludin, identified as a linchpin in regulating BBB integrity, proves to be a pivotal player, with implications extending to the diagnosis of hemorrhagic transformation in ischemic stroke. This study identifies occludin as a potential biomarker, offering promise for early diagnosis and paving the way for novel diagnostic strategies. The analysis highlights the necessity for a more comprehensive exploration of tight junction proteins, including occludin and claudin‐5, particularly in the context of acute cerebral ischemia. The unique healthcare landscape in Kazakhstan adds urgency to the call for further scientific research in this region, emphasizing the need for tailored investigations to address specific regional challenges. This comprehensive overview not only delineates the current state of occludin research but also signals the direction for future investigations. The identified knowledge gaps and emerging trends provide a roadmap for researchers and policymakers alike, with implications for both scientific discourse and clinical practice. Moving forward, a deeper understanding of tight junction proteins, informed by the insights gleaned from this study, holds the potential to shape targeted therapeutic interventions and diagnostic strategies, ultimately contributing to advancements in global stroke care.


  • Establishing prognostic significance of hypoxia predictors in patients with acute cerebral pathology

    by Zhanslu Sarkulova, Ainur Tokshilykova, Alima Khamidulla, Aigul Utepkaliyeva, Dinmukhamed Ayaganov, Marat Sarkulov, Tomas Tamosuitis

    This research aims to study the prognostic role of serum S100 as a predictor of mortality in vascular and traumatic brain injuries.This prospective cohort study involved 219 patients. In the blood ...


  • Open Access

    A long-term follow-up study on biochemical and clinical biomarkers of response to interferon beta-1b treatment in relapsing-remitting multiple sclerosis

    by Anna Pietrzak, Alicja Kalinowska-Lyszczarz, Krystyna Osztynowicz, Alima Khamidulla, Wojciech Kozubski, Slawomir Michalak

    While interferon beta-1b (IFN-β-1b) is still a commonly used disease-modifying drug in the treatment of multiple sclerosis (MS), therapeutic possibilities are expanding, and treatment failure should be identified early. Markers to predict response to IFN-β-1b, either clinical or biochemical, are therefore urgently needed. Interferon-induced proteins, including viperin, suppressor of cytokine signaling 3 (SOCS3), ubiquitin specific peptidase-18 (USP18), and myxovirus resistance protein A (MxA), are possible markers of IFN-β-1b bioavailability and treatment response. To evaluate viperin, SOCS3, USP18 and MxA as markers of treatment response in Polish IFN-β-1btreated patients with MS. In 45 IFN-β-1b-treated Polish patients with MS, serum concentrations of viperin, SOCS3, USP18, and MxA were assessed before and after 24 months of IFN-β-1b treatment. The patients were followed clinically and with magnetic resonance imaging (MRI) for a median of 6.8 years. Low viperin, USP18 and MxA at baseline and 24 months and high SOCS3 at 24 months correlated with higher disease activity up to the 6th year of observation, but only baseline MxA and USP18 were independently related to outcome, with higher concentrations predicting less disease activity in the first 3 years and after the 1st year, respectively. We confirm the predictive value of MxA and propose USP18 as a possible new prognostic biomarker in IFN-β-1btreated MS patients.